Search Results
Search for other papers by M. Schlumberger in
Google Scholar
PubMed
Search for other papers by L. Bastholt in
Google Scholar
PubMed
Search for other papers by H. Dralle in
Google Scholar
PubMed
Search for other papers by B. Jarzab in
Google Scholar
PubMed
Search for other papers by F. Pacini in
Google Scholar
PubMed
Search for other papers by J.W.A. Smit in
Google Scholar
PubMed
Distant metastases are the main cause of death in patients with medullary thyroid cancer (MTC). These 21 recommendations focus on MTC patients with distant metastases and a detailed follow-up protocol of patients with biochemical or imaging evidence of disease, selection criteria for treatment, and treatment modalities, including local and systemic treatments based on the results of recent trials. Asymptomatic patients with low tumor burden and stable disease may benefit from local treatment modalities and can be followed up at regular intervals of time. Imaging is usually performed every 6–12 months, or at longer intervals of time depending on the doubling times of serum calcitonin and carcinoembryonic antigen levels. Patients with symptoms, large tumor burden and progression on imaging should receive systemic treatment. Indeed, major progress has recently been achieved with novel targeted therapies using kinase inhibitors directed against RET and VEGFR, but further research is needed to improve the outcome of these patients.
